Stock News

$0.07 EPS Expected for Summit Midstream Partners, LP (SMLP); Navidea Biopharmaceuticals Has 0.56 Sentiment

Navidea Biopharmaceuticals, Inc (NYSEAMERICAN:NAVB) Logo

Navidea Biopharmaceuticals Inc (NAVB) investors sentiment decreased to 0.56 in 2017 Q4. It’s down -0.80, from 1.36 in 2017Q3. The ratio fall, as 10 investment professionals increased or opened new holdings, while 18 sold and reduced holdings in Navidea Biopharmaceuticals Inc. The investment professionals in our database reported: 12.03 million shares, down from 12.08 million shares in 2017Q3. Also, the number of investment professionals holding Navidea Biopharmaceuticals Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 12 Increased: 8 New Position: 2.

Analysts expect Summit Midstream Partners, LP (NYSE:SMLP) to report $0.07 EPS on May, 3.They anticipate $0.09 EPS change or 56.25% from last quarter’s $0.16 EPS. SMLP’s profit would be $5.22 million giving it 52.87 P/E if the $0.07 EPS is correct. After having $0.25 EPS previously, Summit Midstream Partners, LP’s analysts see -72.00% EPS growth. The stock increased 1.05% or $0.1544 during the last trading session, reaching $14.8044. About 42,417 shares traded. Summit Midstream Partners, LP (NYSE:SMLP) has declined 38.73% since April 13, 2017 and is downtrending. It has underperformed by 50.28% the S&P500.

Among 9 analysts covering Summit Midstream Partners (NYSE:SMLP), 4 have Buy rating, 1 Sell and 4 Hold. Therefore 44% are positive. Summit Midstream Partners had 33 analyst reports since August 7, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Buy” rating and $27.0 target in Monday, September 11 report. The rating was maintained by Goldman Sachs on Thursday, May 12 with “Neutral”. The firm earned “Neutral” rating on Friday, January 27 by Credit Suisse. On Tuesday, July 18 the stock rating was downgraded by Barclays Capital to “Sell”. Robert W. Baird maintained the stock with “Outperform” rating in Friday, August 11 report. The company was maintained on Wednesday, September 20 by Robert W. Baird. Wells Fargo downgraded the shares of SMLP in report on Friday, January 15 to “Market Perform” rating. The company was maintained on Thursday, July 6 by RBC Capital Markets. The company was upgraded on Wednesday, January 11 by Wells Fargo. The stock of Summit Midstream Partners, LP (NYSE:SMLP) has “Buy” rating given on Tuesday, January 16 by RBC Capital Markets.

Summit Midstream Partners, LP focuses on owning, developing, and operating midstream energy infrastructure assets primarily shale formations in North America. The company has market cap of $1.10 billion. The firm provides natural gas gathering, treating, and processing services. It has a 15.11 P/E ratio. It operates in five unconventional resource basins, including the Appalachian Basin, which comprises the Utica and Point Pleasant shale formations in southeastern Ohio, and the Marcellus Shale formation in northern West Virginia; the Williston Basin that consists the Bakken and Three Forks shale formations in northwestern North Dakota; the Fort Worth Basin, which includes the Barnett Shale formation in north-central Texas; the Piceance Basin that comprises the Mesaverde formation, and the Mancos and Niobrara shale formations in western Colorado and eastern Utah; and the DJ Basin, which includes the Niobrara shale formation in northeastern Colorado.

Since March 9, 2018, it had 1 buying transaction, and 2 selling transactions for $149,525 activity. Another trade for 15,000 shares valued at $238,200 was made by Newby Steven J on Friday, March 9. Graves Brad N sold 5,000 shares worth $74,125. Matthews Louise E also sold $14,550 worth of Summit Midstream Partners, LP (NYSE:SMLP) on Monday, March 19.

Investors sentiment increased to 1.24 in 2017 Q4. Its up 0.41, from 0.83 in 2017Q3. It increased, as 8 investors sold Summit Midstream Partners, LP shares while 17 reduced holdings. 12 funds opened positions while 19 raised stakes. 36.88 million shares or 3.16% more from 35.75 million shares in 2017Q3 were reported. Brookfield Asset Management Inc invested in 1.45 million shares. Cushing Asset Mngmt Limited Partnership reported 1.57M shares stake. Penbrook Management Limited Liability Co reported 31,500 shares or 0.58% of all its holdings. Emory University holds 87,560 shares or 1.54% of its portfolio. Deutsche National Bank & Trust Ag, Germany-based fund reported 60,800 shares. California-based Wells Fargo And Mn has invested 0% in Summit Midstream Partners, LP (NYSE:SMLP). Spirit Of America Mgmt Corp Ny reported 0.85% of its portfolio in Summit Midstream Partners, LP (NYSE:SMLP). Citigroup holds 0% or 97,794 shares. Commonwealth Of Pennsylvania Pub School Empls Retrmt holds 0.17% of its portfolio in Summit Midstream Partners, LP (NYSE:SMLP) for 615,271 shares. Evergreen Capital Mgmt Ltd Llc stated it has 360,800 shares. Kayne Anderson Advsr Lp reported 0.87% stake. Blackstone Limited Partnership invested in 0.25% or 3.04 million shares. 668,684 are owned by Goldman Sachs. Citadel Advsr Limited Liability Com stated it has 11,685 shares or 0% of all its holdings. 115,717 are held by Rafferty Asset Mngmt Limited.

The stock decreased 0.91% or $0.0028 during the last trading session, reaching $0.3065. About 137,942 shares traded. Navidea Biopharmaceuticals, Inc (NAVB) has declined 36.81% since April 13, 2017 and is downtrending. It has underperformed by 48.36% the S&P500.

Lifeplan Financial Group Inc holds 0.01% of its portfolio in Navidea Biopharmaceuticals, Inc for 28,810 shares. Advisory Services Network Llc owns 5,250 shares or 0% of their US portfolio. Moreover, Ameriprise Financial Inc has 0% invested in the company for 13,600 shares. The California-based Bailard Inc. has invested 0% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 37,503 shares.

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company has market cap of $49.67 million. The firm develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It has a 0.66 P/E ratio. It is also developing NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinsons disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs and therapeutics.

Navidea Biopharmaceuticals, Inc (NYSEAMERICAN:NAVB) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *